SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-039554
Filing Date
2023-03-31
Accepted
2023-03-31 06:30:13
Documents
15
Period of Report
2023-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2311032d1_8k.htm   iXBRL 8-K 33645
2 EXHIBIT 99.1 tm2311032d1_ex99-1.htm EX-99.1 84267
7 GRAPHIC tm2311032d1_ex99-1img002.jpg GRAPHIC 2013
  Complete submission text file 0001104659-23-039554.txt   356969

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20230331.xsd EX-101.SCH 3314
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20230331_def.xml EX-101.DEF 27169
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20230331_lab.xml EX-101.LAB 36768
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20230331_pre.xml EX-101.PRE 25791
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2311032d1_8k_htm.xml XML 5166
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 23783092
SIC: 2834 Pharmaceutical Preparations